Effects of anti-rheumatic gold salts on NF-κB mobilization and tumour necrosis factor-alpha (TNF-α)-induced neutrophil-dependent cytotoxicity for human endothelial cells

Clinical and Experimental Immunology

Volumn 120, Issue 1, 2000, Pages 79-84

  Bratt, Johan ^a   Belcher, J ^b   Vercellotti, G M ^b   Palmblad, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anti rheumatic drugs; Cytotoxicity; Endothelial cells; Gold salts; NF B

Indexed keywords

GOLD SALT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHEMOTAXIS; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DRUG EFFECT; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

EID: 0034111352     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01190.x     Document Type: Article

References (41)

1. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84:2068-101.
2. Bratt J, Palmblad J. Cytokine induced neutrophil mediated injury of human endothelial cells. J Immunol 1997; 159:912-8.
3. Westlin WF, Gimbrone MA. Neutrophil-mediated damage to human vascular endothelium: role of cytokine activation. Am J Pathol 1993; 142:117-28.
4. Heimburger M, Lerner R, Palmblad J. Effects of antirheumatic drugs on adhesiveness of endothelial cells and neutrophils. Biochem Pharmacol 1998; 56:1661-9.
5. Bratt J, Palmblad J. Inhibition of neutrophil dependent cytotoxicity for human endothelial cells by antirheumatic drugs. J Lab Clin Med 1996; 128:552-60.
6. Bratt J, Palmblad J. Effects of antirheumatic drugs on cytokine induced neutrophil dependent cytotoxicity for human endothelial cells. 1999; Submitted.
7. Hafström I, Udén AM, Palmblad J. Modulation of neutrophil functions by auranofin. Scand J Rheumatol 1983; 12:97-105.
8. Finkelstein AE, Roisman FR, Ladizesky MG, Walz DT. Auranofin and lysosomal enzymes. J Rheumatol 1982; 8:46-53.
9. Kawakami A, Eguchi K, Migita K et al. Inhibitory effects of gold sodium thiomalate on the proliferation and interferon-γ induced HLA-DR expression in human endothelial cells. J Rheumatol 1990; 17:430-5.
10. Corkill MM, Kirkham BW, Haskard DO, Barbatis C, Gibson T, Panayi GS. Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol 1991; 18:1453-60.
11. Read M, Whitley M, Williams A, Collins T. NF-κB and IκB-α: an inducible regulatory system in endothelial activation. J Exp Med 1994; 179:503-10.
12. Collins T, Read MA, Neal AS, Whitley M, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995; 9:899-909.
13. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell 1995; 80:529-32.
14. Beg A, Finco T, Nantermet P, Baldwin A. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκB-α: a mechanism for NF-κB activation. Mol Cell Biol 1993; 15:3301-10.
15. Brockman J, Schierer D, McKinsey T, Hall S, Qi X, Lee W, Ballard D. Coupling of a signal response domain in IκB-α: a mechanism for NF-κB activation. Mol Cell Biol 1995; 15:2809-18.
16. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle P. Rapid proteolysis of IκB-α is necessary in the activation of transcription factor NF-κB. Nature 1993; 365:182-5.
17. Pierce JW, Read MA, Ding H, Luscinskas FW, Collins T. Salicylates inhibit IκB-α phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol 1996; 156:3961-9.
18. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994; 265:956-9.
19. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995; 270:286-90.
20. Bratt J, Lerner R, Ringertz B, Palmblad J. Lipoxin A4 induces neutrophil dependent cytotoxicity for human endothelial cells. Scand J Immunol 1994; 39:351-4.
21. Ringertz B, Palmblad J, Lindgren JÅ. Stimulus-specific neutrophil aggregation: evaluation of possible mechanisms for the stimulus-response apparatus. J Lab Clin Med 1985; 106:132-40.
22. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11:1475-89.
23. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46:705-16.
24. Bessho R, Matsubara K, Kubota M et al. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kB (NF-κB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem Pharma 1994; 48:1883-9.
25. Ferran C, Millan MT, Csizmadia V, Cooper JT, Brostjan C, Bach FH, Winkler H. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Commun 1995; 214:212-23.
26. Baggiolini M, Walz A, Kunkel SL. Neutrophil activating peptide-1/inlerleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989, 84:1045-9.
27. Detmers PA, Lo SK, Olsen-Egbert E, Walz A, Baggiolini M, Cohn ZA. Neutrophil-activating protein-1/interleukin-8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J Exp Med 1990; 171:1155-62.
28. Kunsch C, Rosen CA. NF-κB subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993; 13:6137-46.
29. Moellering D, McAndrew J, Jo H, Darley-Usmar VM. Effects of pyrrolidine dithiocarbamate on endothelial cells: protection against oxidative stress. Free Rad Biol Med 1999; 26:1138-45.
30. Wrighton CJ, Hofer-Warbinek R, Moll T, Eytner R, Bach FH, de Martin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of I kappa B alpha, an inhibitor of the transcription factor NF-kappa B. J Exp Med 1996; 183:1013-22.
31. Yang JP, Merin JP, Nakano T, Kato T, Kitade Y, Okamoto T. Inhibition of the DNA binding activity of NF-kappa B by gold compounds in vitro. Febs Letters 1995; 361:89-96.
32. Daniel LW, Civoli F, Rogers MA, Smitherman PK, Raju PA, Roederer M. ET-18-OCH3 inhibits nuclear factor-kappa B activation by 12-O-tetradecanoylphorbol-13-acelate but not by tumor necrosis factor-alpha or interleukin 1 alpha. Cancer Res 1995; 55:4844.
33. Danis VA, Franic GM, Brooks PM. The effect of slow-acting anti-rheumatic drugs (SAARDs) and combinations of SAARDs on monokine production in vitro. Drugs Exp Clin Res 1991; 17:549-54.
34. Bondeson J, Sundler R. Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages. Biochem Pharmacol 1995; 50:1753-9.
35. Peng HB, Libby P, Liao JK. Induction and stabilization of IκBa by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995; 270:14214-9.
36. Dalton TP, Shertzer HG, Puga A. Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999; 39:67-101.
37. Schieven GL, Kirihara JM, Myers DE, Ledbetter JA, Uckun FM. Reactive oxygen intermediates activate NF-κB in a tyrosine kinase dependent mechanism and in combination with vanadate activate the p56 and p59 tyrosine kinases in human lymphocytes. Blood 1993; 82:1212-20.
38. Finco TA, Beg A, Baldwin A. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc Natl Acad Sci USA 1994; 91:11884-8.
39. Baeuerle P, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12:141-79.
40. Finkelstein AE, Roisman FR, Ladizesky MG, Walz DT. Auranofin and lysosomal enzymes. J Rheumatol Suppl 1982; 8:46-53.
41. Hafström I, Seligmann BE, Friedman MM, Gallin J. Auranofin affects early events in human polymorphonuclear neutrophil activation by receptor-mediated stimuli. J Immunol 1984; 132:2007-13.